A new horizon in pathway biomarkers
Partnership for Breakthroughs in Sarcopenia
A Senior Research Fellow at the University of Southampton is applying TopMD to investigate the molecular drivers of muscle dysregulation in ageing.
>> Learn More
Topology of gene expression predicts outcome
Blood gene expression at hospital admission, analysed with TopMD, predicts COVID-19 ICU risk, enabling improved patient stratification and resource allocation.
>> Learn More
The era of precision medicine
Precision medicine drives biomarker-guided basket, umbrella, and platform trials, improving therapy customization, though biological rationale and understanding of these designs remain limited.
>> Learn More
Complete RNA-seq analysis without the overhead. Where most researchers wrestle with scripts, package conflicts, and compute clusters, GAS delivers the same rigour through a browser — on any device, from anywhere.
- ✓No installation, no command line, no HPC — cloud-native
- ✓FASTQ to publication-ready figures in a single automated run
- ✓Differential expression, PCA, UMAP, clustering, boxplots
- ✓Output feeds directly into MecStra or BioMapper
Conventional clustering forces patients into discrete groups. BioMapper doesn't. It preserves the continuous shape of your data — revealing trajectories, gradients, and rare subpopulations that disappear when you assign labels too early.
- ✓Captures disease trajectories and transitional phenotypes — not just endpoints
- ✓Detects rare subpopulations invisible to k-means, hierarchical, and graph-based methods
- ✓No forced cluster boundaries — biology dictates the structure, not the algorithm
- ✓Reactome pathway enrichment at node level — links topology directly to mechanism
- ✓Runs on GAS output or any normalised omics matrix
Purpose-built for the hardest problem in precision medicine: finding patient subtypes that respond differently to treatment — and understanding why, at the pathway level.
- ✓Network-aware pathway scoring — captures biological interactions, not just expression levels
- ✓Outcome-informed subtypes linked to differential treatment response
- ✓Cross-platform validated — profiles generalise from discovery to independent cohorts
- ✓AI interpretation of subtype biology with peer-reviewed citations
- ✓Validated in real-world asthma cohorts — 92% vs 44% responder enrichment
All three tools. One licence.
Access GAS, BioMapper TDA, and MecStra as a connected suite — from raw sequencing data to mechanistic patient stratification. Academic and commercial pricing available.